# A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

> **NCT02000440** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 17 (actual)

## Conditions studied

- Glomerulosclerosis, Focal Segmental

## Interventions

- **DRUG:** Losmapimod

## Key facts

- **NCT ID:** NCT02000440
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-01
- **Primary completion:** 2016-02-29
- **Final completion:** 2016-05-11
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000440, "A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02000440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*